Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023
Reportbuyer.com just published a new market research report: Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023.
London (PRWEB) September 25, 2013
Contract manufacturing for pharma – discover top companies' revenue prospects
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.
Our study analyses 30 leading CMOs. There you discover how revenues from drug production services can increase.
That way you find information you need on established and emerging companies. Learn on to scan those organisations and see what their future market could be worth.
Forecasts and other data to help you stay ahead
In our new study you find analytical profiles of 30 top companies, and analyses of the overall industry. You discover historical data, market shares, revenue forecasts, and growth rates. See, too, qualitative analysis, business outlooks and developments.
There you also gain 141 tables, 58 charts, and five interviews with the industry.
Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in knowledge of the CMO industry and market:
•Finished dosage formulations (FDF) manufacturing
•Active pharmaceutical ingredients (API) production.
See now how you can benefit your research, analyses and decisions, also saving time. The following sections highlight what you find in our new investigation.
Company profiles – activities, results, competition, and prospects
Our report analyses 30 leading companies. The content of each profile differs, depending on the company. In general, though, a profile gives you the following information:
•Overview of the company's contract manufacturing services, including clients
•Analysis of recent financial performance – overall revenue and that for CMO services
•Assessment of developments – acquisitions, capacity expansions, new service offerings, and collaborations
•SWOT analysis of the company – strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2013 to 2023
•Forecasting of pharmaceutical contract manufacturing revenues to 2023, for 23 of the companies
•Transcript of an interview by visiongain, for five of the companies.
Discover there what participants achieve, do, and say, helping you stay ahead.
European contract manufacturing organisations
First, our study gives you discussions, financial analyses, and commercial outlooks for 15 European CMOs, including these:
•Boehringer Ingelheim Biopharmaceuticals
Discover what the future holds for those pharma service providers, including revenue outlooks to 2023.
Companies based in the US and Japan
Next, our report shows you developments and sales outlooks to 2023 for five other companies:
•Catalent Pharma Solutions
•AbbVie Contract Manufacturing
Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues possible from 2013. You see where prospects exist.
Developed-market API specialists
You also discover outlooks for four top producers of active pharma ingredients:
Our report shows you potentials of the industry. You see possibilities for advancing technology and raising business performance.
India and China – analysis of pharma manufacturing service providers
Our work also assesses six Indian and Chinese companies. There you discover activities and prospects of these firms:
•Dr. Reddy's Laboratories
•Shandong Xinhua Pharmaceutical
•Zhejiang Hisun Pharmaceutical
•Zhejiang Huahai Pharmaceuticals.
That way you find sales data and underlying trends, seeing what the present and future hold.
Predictions for the worldwide pharma CMO market and submarkets
Our report also forecasts revenues to 2023 for the world contract manufacturing industry and its main segments: APIs and FDFs.
There you see overall world revenues in 2017 reaching $66.4bn. Our analyses reveal high growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper. She how and where, finding potential.
Biologics and biosimilars also hold promise. New biological therapies – including antibody-drug conjugates and regenerative medicines – interest CMOs and clients.
Discover opportunities and revenue predictions, then, for outsourced production of medicines. You investigate established and rising companies, finding their prospects.
Six ways Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023 helps you
In particular, our new investigation gives you the following knowledge:
•Revenues to 2023 for the world CMO market and its components – discover that industry's prospects, finding promising places for investments and revenues
•Profiles of 30 leading companies – assess services, strategies, sales results and outlooks, also gaining revenue forecasts to 2023 for 23 of the organisations
•Interviews with 5 companies in the CMO industry – discover debates and opinions to help you stay ahead
•Competition and opportunities – see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
•Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and gain advantages
•Outlooks for established players and firms entering the sector – explore needs, practices, and outlooks for future success.
Information found nowhere else
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.
Prospects for pharma manufacturing providers – gain by ordering now
Our study lets you find data, trends, opportunities, and commercial predictions for outsourced drug and API production. Avoid missing out – please order our new report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
AbbVie Contract Manufacturing
Abic (part of Teva)
Aerofarm (part of Fareva)
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM) [France]
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
AlgoNomics (part of Lonza)
Alliance Medical Products (part of Siegfried)
Archimica (part of Euticals)
AuroSource (part of Aurobindo Pharma)
Banner Pharmacaps (part of Patheon)
Barr-Pliva (part of Teva)
Beijing Double-Crane Pharmaceutical (BDCP)
Bellwyck Packaging Solutions
Bentley Pharma (part of Teva)
Boehringer Ingelheim Biopharmaceuticals
Catalent (Shanghai) Clinical Trial Supplies Co
Catalent Pharma Solutions
China National Pharmaceutical Group (Sinopharm)
Chirotech Technology (part of Dr. Reddy's Laboratories)
Cobra Biologics Holding
CordenPharma (part of ICIG)
CPM ContractPharma (part of Aenova)
Dr. Reddy's Laboratories
DSM Sinochem Pharmaceuticals
Eclipse Therapeutics (part of Bionomics)
Eindhoven University of Technology
Enobia Pharma (now Alexion Pharmaceuticals)
Esteve Química (part of Esteve)
Euro Vital Pharma (part of Aenova)
European Medicines Agency (EMA)
Evonik Degussa (part of Evonik Industries)
Excella (part of Fareva)
Excelvision (part of Fareva)
Farma Lepori (part of Angelini Group)
Farmaclair (part of Fareva)
Farmea (part of Fareva)
Food and Drug Administration (FDA) [US]
Fuyang Xinghai Investment
Genentech (part of Roche)
Générique Même Médicament (GEMME) [France]
Genzyme (part of Sanofi)
Gyma Laboratories of America
Health and Safety Executive (HSE) [UK]
Human Genome Sciences (part of GSK)
ICI (Imperial Chemical Industries)
Instituto de Angeli (part of Fareva)
International Chemical Investors Group (ICIG)
Ivax API (part of Teva)
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
National Institutes of Health (NIH) [US]
National Institutes of Health Center for Regenerative Medicine (NIH CRM) [US]
New Jersey Institute of Technology
OctoPlus (part of Dr. Reddy's Laboratories)
OmniChem (part of Ajinomoto OmniChem)
PFC (now Teva PFC)
Pfizer CentreSource (part of Pfizer)
Piramal Pharma Solutions (part of Piramal Enterprises)
Plantex (part of Teva)
Poli Industria Chimica (part of Euticals)
R5 Pharmaceuticals (part of Aesica Pharmaceuticals)
Ranbaxy Laboratories (part of Daiichi Sankyo)
Respirics (part of Zhejiang Hisun Pharmaceutical)
Saltigo (part of Lanxess)
Sandoz (part of Novartis)
Sanwa Kagaku Kenkyusho Co
Sentry BioPharma Services
Shandong Xinhua Pharmaceutical (Europe) (part of Shandong Xinhua Pharmaceutical)
Shandong Xinhua Pharmaceutical Co
Shanghai Pharmaceutical Co
Sicor Biotech (part of Teva)
Sigmar Italia (part of Fareva)
Softigel (part of Procaps)
State Food and Drug Administration (SFDA) [China]
SurModics (part of Evonik Industries)
SwissCo Services (part of Aenova)
Takeda Pharmaceutical Company
Temmler Group (part of Aenova)
Temmler Ireland (part of Aenova)
Temmler Italia (part of Aenova)
Temmler Pharma (part of Aenova)
Temmler Werke (part of Aenova)
Teva Pharmaceutical Industries
Théramax (part of Teva)
Thermo Fisher Scientific
Tianjin Tianyo Pharmaceuticals
University of Bradford
University of Leeds
Valdepharm (part of Fareva)
Vivante GMP Solutions (part of Lonza)
Wanhuai Beijing Double-Crane Pharmaceutical (part of BDCP)
West Pharmaceutical Services
Xinhua Pharmaceutical (Gaomi) Company (part of Shandong Xinhua Pharmaceutical)
Yiwu Huayi Investment
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Jiang Yuan Tang Biotechnology
Zibo Xinhua-Perrigo Pharmaceutical Company
Read the full report:
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11160582.htm